- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.12. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ... | - | HKEx | ||
| 03.11. | Neurocrine pens $880M deal with China's TransThera for red-hot immunology target | 12 | FierceBiotech | ||
| 03.11. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT COLLABORATION WITH NEUROCRINE | 4 | HKEx | ||
| 20.10. | TRANSTHERA-B (02617): INSIDE INFORMATION ANNOUNCEMENT PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx | ||
| 25.09. | A wild ride for TransThera investors: what's the story? | 1 | Bamboo Works | ||
| 19.09. | TRANSTHERA-B (02617): INTERIM REPORT 2025 | 2 | HKEx | ||
| TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln | |||||
| 16.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS | 1 | HKEx | ||
| 10.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT PHASE II IND APPROVAL OF TINENGOTINIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF PREVIOUSLY TREATED ... | - | HKEx | ||
| 04.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH AKESO'S (CADONILIMAB, ... | - | HKEx | ||
| 25.08. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS A CONSTITUENT OF THE HANG SENG INDEX SERIES | 1 | HKEx | ||
| 25.08. | TRANSTHERA-B (02617): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | 1 | HKEx | ||
| 25.08. | TRANSTHERA-B (02617): CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | - | HKEx | ||
| 13.08. | TRANSTHERA-B (02617): DATE OF BOARD MEETING | - | HKEx | ||
| 04.08. | TRANSTHERA-B (02617): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 4 AUGUST 2025 | - | HKEx | ||
| 11.07. | TRANSTHERA-B (02617): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 4 AUGUST 2025 | 2 | HKEx | ||
| 11.07. | TRANSTHERA-B (02617): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 11.07. | TRANSTHERA-B (02617): CIRCULAR OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 10.07. | TRANSTHERA-B (02617): NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS TO REGISTERED SHAREHOLDERS | 2 | HKEx | ||
| 10.07. | TRANSTHERA-B (02617): NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS TO NON-REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 24.06. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT GRANT OF TINENGOTINIB (TT-00420) FAST TRACK DESIGNATION FOR TREATMENT OF MCRPC | 1 | HKEx |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,345 | -0,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| COGENT BIOSCIENCES | 41,690 | +4,12 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| LENZ THERAPEUTICS | 18,180 | -25,83 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ) in South Korea for the Treatment of Presbyopia | SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus... ► Artikel lesen | |
| BIONTECH | 80,90 | -1,04 % | Märkte am Morgen: Nvidia, Netflix, Paramount Skydance, Bayer, HelloFresh, BioNTech, ASML | Die Sitzung der US-Notenbank am Mittwoch ist das beherrschende Thema in dieser Woche. Am deutschen Aktienmarkt zeigte sich der DAX im Vorfeld zurückhaltend, schloss aber immerhin leicht in der Gewinnzone.... ► Artikel lesen | |
| VOR BIOPHARMA | 12,830 | +5,51 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 37,810 | +4,88 % | JAMA zeichnet Studie zu Bluthochdruck-Medikament von Mineralys als Spitzenforschung 2025 aus | ||
| RECURSION PHARMACEUTICALS | 4,415 | -3,60 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 32,920 | +4,34 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| ARCUS BIOSCIENCES | 22,080 | -12,21 % | Arcus Biosciences And Gilead Discontinue Phase 3 STAR-221 Study In Cancer Due To Futility | FOSTER CITY (dpa-AFX) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Friday the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,70 | +0,14 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| VERA THERAPEUTICS | 49,170 | +6,84 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 88,00 | +0,22 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,510 | 0,00 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 68,22 | +1,16 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOVANT | 26,280 | +5,92 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails |
Das Unternehmen TRANSTHERA SCIENCES NANJING INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSTHERA SCIENCES NANJING INC finden Sie auf Wallstreet Online.